MIRA PHARMACEUTICALS, INC. (MIRA): M&A transaction — MIRA completes SKNY acquisition, adds three pipeline programs; regains Nasdaq compliance

MIRA PHARMACEUTICALS, INC.

Acquired 100% of SKNY for restricted MIRA shares; SKNY contributed $5M in marketable securities to MIRA.
Pipeline now includes Ketamir-2 (Phase 1 neuropathic pain), MIRA-55 (oral THC analog), and SKNY-1 (obesity/smoking cessation).
Nasdaq had notified MIRA of stockholders' equity deficiency in April 2025; extension granted to Oct 6, 2025.
After merger closing and ATM sales, MIRA believes it has regained compliance; Nasdaq will continue to monitor.
No specific exchange ratio or deal value disclosed; valuations were independent third-party.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

MIRA PHARMACEUTICALS, INC. completed an acquisition involving SKNY Pharmaceuticals, Inc. for restricted shares of the Company’s common stock (closed 2025-09-29).

Action: acquisition
Counterparty: SKNY Pharmaceuticals, Inc.
Consideration: restricted shares of the Company’s common stock
Closing: 2025-09-29

Exact text from the filing

On September 29, 2025, MIRA Pharmaceuticals, Inc. (the “Company”) completed its acquisition of SKNY Pharmaceuticals, Inc. (“SKNY”) pursuant to the previously announced merger agreement (the “Merger Agreement”).

View on SEC.gov

Browse all m&a transactions →

MIRA PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-25-016168

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.